Biotechnology company 10x Genomics and Harvard University reached a Feb. 6 settlement in a patent lawsuit that they jointly ...

Biotech company 10x Genomics (NASDAQ:TXG) will be reporting earnings tomorrow after market hours. Here’s what to look for. 10x Genomics missed analysts’ revenue expectations by 5% last quarter ...

10x Genomics Price Performance Shares of TXG opened at $12.31 on Tuesday. The firm has a market cap of $1.49 billion, a PE ratio of -8.05 and a beta of 1.85. The stock’s fifty day moving average ...

Genomics reported a Q4 EPS loss of $(0.40), missing estimates, while revenue declined 10% year over year. Analysts lowered ...

Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results beating Wall Street’s revenue expectations , but sales fell by 10.3% year on year to $165 million. On the other hand, ...

Genomics company 10x and Harvard University have agreed to resolve a patent lawsuit against 10x's rival Vizgen four days into a scheduled two-week trial, according to a Thursday filing in Delaware ...

Leerink Partners lowered 10x Genomics from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $25.00 to $12.00 in a research report on Thursday.

Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The company’s shares closed yesterday at $11.94.

Barclays lowered the firm’s price target on 10x Genomics (TXG) to $15 from $18 and keeps an Overweight rating on the shares.Maximize Your ...

10X Genomics reported a Q4 2024 EPS of -$0.40, below the forecast of -$0.31. Revenue for the quarter was $165 million, exceeding expectations but down 10% year-over-year. The stock dropped 6.75% ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...